Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In a prior clinical evaluation, applying multiplex testing to samples that had already returned negative results under single-pathogen methods still uncovered dozens of missed infections. The authorization builds on Seegene's earlier FDA clearance for a two-target HSV assay and expands the company's footprint in U.S. syndromic testing. In a conversation with Pharmaceutical Executive, Dr. Gurinder Sidhu, Pfizer's U.S. antiviral medical lead, pushed back on clinician complacency around Covid-19 antivirals as hospitalization rates have declined from early pandemic levels. Thanks for listening to Pharmaceutical Executive Daily.